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Rescue of the MeRtK phagocytic 
defect in a human ipsC disease 
model using translational read-
through inducing drugs
Conor M. Ramsden  1,2,3, Britta Nommiste1, Amelia R. Lane1, Amanda-Jayne F. Carr  1, Michael 
B. powner1,4, Matthew J. K. smart1, Li Li Chen1, Manickam N. Muthiah2,3, Andrew R. Webster1,2, 
Anthony T. Moore1,2,5, Michael E. Cheetham1, Lyndon da Cruz1,2,3 & Peter J. Cofey1,2,6
Inherited retinal dystrophies are an important cause of blindness, for which currently there are no 
efective treatments. In order to study this heterogeneous group of diseases, adequate disease 
models are required in order to better understand pathology and to test potential therapies. Induced 
pluripotent stem cells ofer a new way to recapitulate patient speciic diseases in vitro, providing an 
almost limitless amount of material to study. We used ibroblast-derived induced pluripotent stem cells 
to generate retinal pigment epithelium (RPE) from an individual sufering from retinitis pigmentosa 
associated with biallelic variants in MERTK. MERTK has an essential role in phagocytosis, one of the 
major functions of the RPE. The MERTK deiciency in this individual results from a nonsense variant 
and so the MERTK-RPE cells were subsequently treated with two translational readthrough inducing 
drugs (G418 & PTC124) to investigate potential restoration of expression of the afected gene and 
production of a full-length protein. The data show that PTC124 was able to reinstate phagocytosis of 
labeled photoreceptor outer segments at a reduced, but signiicant level. These indings represent a 
conirmation of the usefulness of iPSC derived disease speciic models in investigating the pathogenesis 
and screening potential treatments for these rare blinding disorders.
Inherited retinal dystrophies represent a heterogeneous group of diseases, which are now the most common cause 
of registered blindness in the working age population in the UK1. Few naturally occurring disease models exist for 
this group of disorders. Furthermore, access to afected retina and retinal pigment epithelium (RPE) is restricted, 
providing a very limited amount of human tissue to study. With the advent of induced pluripotent stem cell 
(iPSC) technology2 disease speciic human models can be generated in vitro with a theoretically limitless supply of 
cells that can be diferentiated to the tissue of interest to study these diseases and test drugs or genetic therapies3, 4.
he RPE is a cellular monolayer that has an essential supporting role to the photoreceptors in the retina, being 
involved in retinol cycling, nutrient transport, growth factor production and phagocytosis of the discarded pho-
toreceptor outer segments5.
MER receptor tyrosine kinase (MERTK) is a tyrosine kinase that is expressed at the apical surface of the RPE. 
It is a key regulator of the recognition and internalisation of photoreceptor outer segments (POS) during the 
process of phagocytosis by RPE cells6. he MERTK protein is a 999 amino acid polypeptide with a molecular 
weight of 110 kDa, which is subject to post-translational modiications such as N-linked glycosylation7. MERTK 
deiciency results in a form of retinitis pigmentosa, RP38, a rod cone dystrophy for which there is no efective 
treatment8.
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Recently, the results of a gene therapy trial with AAV2 mediated delivery of MERTK to RP38 individuals have 
been published, with mixed results9. his highlights the requirement for new strategies to test potential therapeu-
tics for these genetic disorders. One potential method is to target a speciic variant using small molecules. In the 
case of RP38, several of the known human MERTK variants result in a premature stop codon10–14. In these cases, a 
potential strategy is to employ translational readthrough inducing drugs (TRIDs), which stimulate the bypass of 
the premature stop codon15. his allows continuation of translation, restoring a full-length protein. TRIDs have 
been shown to be efective in restoring protein and function in previous studies of iPSC-RPE from an individual 
with X-linked retinitis pigmentosa caused by a mutation in RP216.
In this study, we have generated ibroblasts cells from a skin biopsy of an individual with compound heterozy-
gous variants in the MERTK gene. hese cells were then reprogrammed to iPSC and diferentiated into mature 
RPE cells with an aim to characterise this iPSC derived model of MERTK retinitis pigmentosa, and employ TRIDs 
to restore MERTK function.
Results
Characterisation of MERTK variant clinical phenotype and iPSC derived RPE. We obtained a skin 
biopsy from a 26-year-old male (GC15566) with compound heterozygous variants in the MERTK gene, consisting 
of a single base change in the irst base of intron 1 (61+1 G>A) and a nonsense variant in exon 14 (1951 C>T)13. 
Snellen visual acuity was 6/36 in the right eye and 3/60 in the let. Fundus examination revealed bilateral central 
retinal degeneration, consistent with an inherited maculopathy, bilateral optic nerve head pallor and narrowed 
and atrophic retinal blood vessels (Fig. 1A). here were no areas of hyperpigmentation noted in the peripheral 
retinal examination. Optical coherence tomography (Spectralis, Heidelberg) shows an increased right macular 
retinal thickness nasally, a mild degree of epiretinal ibrosis, general preservation of the outernuclear layer but 
intermittent loss of the ellipsoid zone and RPE layers (Fig. 1B). Blue light, wideield autoluorescence (Optos) 
shows a hypoluorescence centrally, matching the area of central macular degeneration with general preservation 
of the periphery apart from a few punched out lesions outside the macular area (Fig. 1C). Adaptive optics assisted 
lash photographs taken with the Rtx-1 fundus camera (ImagineEyes) of the right eye at 5 degrees superior to the 
fovea (grey box on Fig. 1A) shows disorganised, scattered relections consistent with photoreceptor loss (Fig. 1D). 
Macular microperimetry (Nidek) shows reduced retinal sensitivity at the macula (Fig. 1E), with the blue collec-
tion of spots marking the ixation of the eye.
Dermal ibroblasts were expanded from the biopsy and reprogrammed into iPSC using episomal vectors in 
parallel with a control human BJ ibroblast cell line (Figure S1A–C). he iPSC were diferentiated into RPE using 
a spontaneous method of diferentiation17. Pigmented RPE cells were manually puriied and cultured as a mon-
olayer that gradually re-pigmented ater 6–8 weeks (Fig. 2).
Control iPSC derived RPE (control RPE) and MERTK deicient iPSC derived RPE (MERTK-RPE) had sim-
ilar cobblestone morphology and pigmentation (Fig. 2A1,2). Electron microscopy revealed the presence of 
basal nuclei, apical microvilli, tight junctions and melanosomes in both control and MERTK-RPE (Fig. 2B1,2). 
Sectioned monolayers of both RPE cells showed highly polarised and mature cells expressing the RPE-associated 
marker proteins PMEL17, PAX 6, CRALBP and RPE65 (Fig. 2C1,2). Integrin αV was detectable in both control 
and MERTK-RPE cells, at their apical surface (Fig. 2D).
MERTK mRNA was expressed in both the control RPE and MERTK-RPE, but at a lower level in the 
MERTK-RPE (Fig. 2E). However, the MERTK protein was only detectable in the control RPE, whilst the CRALBP 
protein, an RPE cell marker was present in both control RPE and MERTK-RPE at equal levels (Fig. 2D,E). 
Analysis of the MERTK gDNA sequence conirmed a change in the irst base of intron 1, as previously described13. 
Within the coding sequence of the gDNA ive heterozygous variants were detected (Figure S2), two missense, 
two synonymous and one nonsense. Analysis of the MERTK cDNA prepared from MERTK-RPE cells showed 
only the wild type sequence at the exon 1/2 border (Fig. 2F). In the MERTK cDNA from the MERTK-RPE, 
only one variant was observed at each of the ive positions that had been noted to be heterozygous in the gDNA 
(Figure S2). Of these ive, only one difered from the wild type, NCBI sequence. his was the C>T variant at cod-
ing position 1951, leading to a premature stop codon in exon 14 (Fig. 2G). here was no evidence of a truncated 
MERTK protein by Western blot analysis, suggesting that if a truncated protein was produced it is unstable and 
degraded (Fig. 2D).
MERTK iPSC derived RPE are unable to phagocytose. he proposed function of MERTK in RPE 
cells is to mediate the engulfment of POS during phagocytosis6, 18. To test this hypothesis in our MERTK-RPE, we 
modiied established phagocytosis assays19, 20, exposing the RPE cells to isolated POS in vitro. Four hours ater the 
addition of isolated POS to both the control and MERTK-RPE, POS are clearly visible inside the control RPE by 
electron microscopy (Fig. 3A), with none observed in the MERTK-RPE (data not shown). Ater 6 hours of POS 
exposure, FITC labeled POS are clearly visible inside the control RPE but were not observed in the MERTK-RPE 
on confocal orthogonal stacks (Fig. 3C,D) (26.33 POS internalised/0.01 mm2 in control RPE, SEM = 2.99; 0.44 in 
MERTK-RPE, SEM = 0.34; n = 9; p < 0.000001).
Translational readthrough inducing drugs are able to restore expression of MERTK in the 
MERTK-RPE and improve phagocytosis. Treatment of the MERTK-RPE cells with 750 µM of the amino-
glycoside G418 resulted in the detection of an immunoreactive species with the expected mobility of the MERTK 
protein. his immunoreactive species was not present in the vehicle treated MERTK-RPE cells by Western blot 
analysis (Fig. 4A). his rescue of some detectable protein with G418, did not appear to restore phagocytic func-
tion in the MERTK-RPE as revealed by the phagocytosis assay (Fig. 4B) (0.11 in untreated, SEM 0.11; 0.55 treated, 
SEM = 0.33; n = 9; p > 0.1). Furthermore, when control RPE was treated with G418, phagocytosis was reduced 
compared to the vehicle treated, suggesting G418 may inhibit POS phagocytosis (40.22 in untreated, SEM = 5.02; 
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15.44 in treated, SEM = 4.46; n = 9; p < 0.001) and this could mask any restoration of MERTK function in the 
MERTK-RPE.
Treatment with the small molecule PTC124 (10 µgml−1), led to the detection of a MERTK immunoreactive 
species of the correct mobility by Western blot analysis that was not present in vehicle-treated MERTK-RPE cells 
(Fig. 4C). MERTK immunoreactivity was also detectable on immunocytochemistry in the MERTK-RPE treated 
with PTC124 (Fig. 4D).
Furthermore, the treatment with 10 µgml−1 PTC124 in MERTK-RPE cells stimulated an increase in phago-
cytic activity (12% of control RPE level) ater 6 hours exposure to POS in vitro (0.22 in untreated, SEM = 0.22; 
3.22 in treated, SEM = 0.85; n = 9; p = 0.002). Importantly, treatment with PTC124 did not seem to have an efect 
on control RPE phagocytic activity (Fig. 4E,F).
Discussion
A deeper phenotyping of this individual with variants in MERTK reveals that, outside the macula area, there is 
little hyperpigmentation, a sign of irreversible retinal damage. In addition, there is some preservation of the gross 
retinal anatomy and persistence of the retinal layers, displayed by OCT. Furthermore, while there is evidence of 
Figure 1. Phenotypic characterisation of an individual with MERTK associated retinal dystrophy. (A) Fundus 
photo of the right eye showing the optic nerve (white arrows), retinal vessels (black arrows) and macula 
area (yellow circle). (B) Optical coherence tomography at the right fovea showing epiretinal ibrosis (white 
arrow), the outernuclear layer (*) and expected position of the ellipsoid layer (black arrow). (C) Wideield 
Optos autoluorescence image of the right retina showing the macula (yellow circle) and peripheral retina. (D) 
ImagineEyes adaptive optics image of the right retina at 5 degrees superior to the fovea (grey box on panel A). 
(E) Interpolated map of Nidek microperimetry of the right macula, with decibel scale (collection of blue points 
in centre of macula = ixation). (F) Schematic of MERTK gene displaying the exons (yellow), the two variants 
(arrows), one in the irst base of intron 1, predicted to interfere with splicing and a premature stop in exon 14, 
and the protein domains of MERTK.
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photoreceptor loss on adaptive optical imaging, there is some preservation of function as outlined by the 
microperimetry. Not only is there some ability to see a stimulus above the baseline, the individual has good 
ixation, throughout the test. Further evidence that this represents a less severe case of MERTK-RP comes from 
Figure 2. Characterisation of control and MERTK-RPE. (A1,2) Light micrograph of control and MERTK-
RPE cells in culture (scale bar 50 µm). (B1,2) Electron micrograph of control and MERTK-RPE (scale bar 
1 µm). (C1,2) Immunocytochemistry of iPSC derived RPE (scale bar 40 µm). (D) Immunohistochemistry of 
the control RPE and MERTK-RPE (scale bar = 10 µm). (E) RT PCR gel electrophoresis and Western blot of the 
MERTK gene and protein in the control RPE and MERTK-RPE. (F) gDNA sequence from MERTK ibroblasts 
of the exon 1/intron 1 junction of the MERTK gene compared to the corresponding MERTK-RPE derived 
cDNA sequence at the exon 1/exon 2 border. (G) gDNA sequence of MERTK ibroblasts compared to MERTK-
RPE cDNA sequence in exon 14 of the MERTK gene.
www.nature.com/scientificreports/
5Scientific RepoRts | 7: 51  | DOI:10.1038/s41598-017-00142-7
comparison with other individuals with variants in MERTK8–14. he results of the phenotyping displayed in Fig. 1 
are thus encouraging, as any translation of therapy would have its best results in a milder disease form.
From a skin biopsy of this individual with compound heterozygous variants and predicted loss of function 
in the MERTK gene we derived dermal ibroblasts which were reprogrammed to iPSC and then diferentiated 
into RPE cells. hese RPE cells have many of the characteristics of primary RPE cells; they grow as a epithelial 
monolayer with a cobblestone appearance, contain apical pigmented melanosomes, basal nuclei and express pro-
teins involved in the process of retinol cycling21. Both the control RPE and the MERTK-RPE express the MERTK 
mRNA as evidenced by RT-PCR but the MERTK-RPE mRNA was present at a lower level. his diference in 
expression was more pronounced at the protein level with total absence of detectable MERTK protein in the 
MERTK-RPE.
he gDNA sequence of the MERTK gene in the MERTK variant individual revealed ive heterozygous variants 
within the coding sequence. However, at each of these positions in the MERTK cDNA from the MERTK-RPE, 
only one of the variants was detectable. his suggests that only one allele is expressed; this is the allele that 
includes the premature stop codon in exon 14. We also examined the sequence at the exon 1/2 border as the indi-
vidual’s MERTK genomic sequence suggested that the variant in intron 1 would likely lead to a diferent splicing 
pattern and the insertion of an extra 11 codons between exon 1 and exon 213. Our analysis of the MERTK cDNA 
sequence from the MERTK-RPE revealed a sequence at the exon 1/2 border that matches that of the normal 
MERTK transcript (NM_006343.2 NCBI database). hese data are consistent with the hypothesis that the allele 
carrying the variant in the irst base of intron 1 is not expressed at the RNA level or is rapidly removed. However, 
the allele carrying the premature stop codon in exon 14 is detectable. his suggests that in this case, the MERTK 
defect could be amenable to TRIDs.
Both the control RPE and MERTK-RPE express Integrin αV, a protein required for the rhythmic activation 
of MERTK18, at the apical surface, suggesting that the cells are otherwise primed for phagocytosis. Functional 
phagocytosis by the control RPE cells was conirmed by electron microscopy following exposure to isolated POS. 
he POS were clearly engulfed and internalised by the control RPE following a 4 hour exposure to POS. In con-
trast, no internalised POS were observed in the MERTK-RPE cells. Internalisation of FITC-labeled POS was 
also observed and quantiied in control RPE using confocal stack analysis. In comparison to the control RPE, no 
internalised POS were observed in MERTK-RPE cells. In addition, it became evident in the control RPE that a 
6-hour time point was preferable to a 20-hour assay time point, as at this longer interval, the FITC luorophore is 
Figure 3. MERTK-RPE are unable to phagocytose. (A) Electron micrograph of the apical surface of the control 
RPE 4 hours following the addition of isolated photoreceptor outersegments (POS) *. (B) Schematic of the 
process of POS phagocytosis by RPE using FITC labeled POS. (C) Orthogonal representations of confocal 
Z stacks of the control RPE and MERTK-RPE 6 hours following the addition of FITC labeled POS (scale 
bar = 20 µm), arrows highlight POS. (D) Graphical representation of phagocytosis between control RPE and 
MERTK-RPE at 6 and 20 hours (error bars represent the mean ±1SEM and p value derived from students 
t-test).
www.nature.com/scientificreports/
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likely degraded by the RPE cells. A comparison of the number of bound but not internalised POS was measured 
between the control and MERTK-RPE during phagocytosis (Figure S3). he diference just reached signiicance 
by t-test (0.03) and this minor diference could be accounted for by the small contribution of MERTK to binding 
POS, rather than the major contribution of Integrin αVβ5 in binding POS. his suggests that the major diference 
noted in phagocytosis between the control and MERTK-RPE occurs at the internalisation phase.
Exposure of the MERTK-RPE to G418, an aminoglycoside related to the antibiotic gentamicin, was able to 
restore expression of a protein of similar size to MERTK that was not present in the untreated cells. However, this 
restoration of protein did not correlate into a functional rescue, as the MERTK-RPE were still unable to phagocy-
tose POS. his might be due to a toxic efect of the G418 as it was noted that the control RPE had decreased levels 
of phagocytosis in the presence of the G418. Aminoglycosides are known to be toxic to the retina22, but the exact 
mechanism is not clear23. Interference with normal RPE function could be a potential mechanism. G418, one of 
the more toxic aminoglycosides, is thought to cause toxicity by binding to mitochondrial ribosomes which are 
similar to prokaryotic ribosomes. In doing so they inhibit mitochondrial protein synthesis and cause oxidative 
stress. RPE are known to have high levels of mitochondria in order to provide energy for processes like phagocy-
tosis which may render them particularly sensitive the aminoglycoside toxicity24.
Following treatment of the MERTK-RPE with another TRID, PTC124, a small molecule which has been 
approved by the European Medicines Agency for Duchenne muscular dystrophy25, we were able to restore expres-
sion of MERTK in the MERTK-RPE. he immunoreactivity was present, however, as multiple bands. One expla-
nation for this is that the protein is diferentially post-translationally modiied depending on which amino acid is 
used during the readthrough process. Furthermore, in a phagocytosis assay, the PTC124 treatment restored 12% 
of the phagocytic function to the MERTK-RPE cells. It is debatable whether an improvement of 12% would be 
Figure 4. Translational readthrough inducing drugs are able to restore expression of MERTK in the MERTK-
RPE and have an efect on phagocytosis. (A) Cropped Western blot of the MERTK protein in control RPE and 
MERTK-RPE treated with G418. (B) Outcome of phagocytosis assay with and without G418 in control RPE and 
MERTK-RPE. (C) Cropped Western blot of MERTK protein in control and MERTK-RPE treated with PTC124. 
(D) Immunocytochemistry of MERTK protein in MERTK-RPE treated with PTC124, arrows highlight MERTK 
expression (scale bar 10 µm). (E) Outcome of phagocytosis assay with and without PTC124 in control and 
MERTK-RPE. (F) 3D model derived from confocal stack, viewed from below, showing MERTK-RPE treated 
with PTC124, 6 hours ater the addition of PTC124; arrows show internalised POS (error bars represent the 
mean ± 1SEM and p values derived from students t-test).
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enough in vivo to slow the progression of the disease. PTC124 has been used to treat Duchenne muscular dystro-
phy26 and cystic ibrosis27. In the preclinical studies of PTC124 for treatment of Duchenne muscular dystrophy 
(DMD), the drug was able to restore 20% of the protein in a mouse model of the disease and this partially restored 
protein was shown to localise to the correct cellular compartment in all muscles biopsied. In addition, the treated 
mice exhibited improved protection from induced injury, an established assay of DMD progression in the model. 
In phase 1 clinical trials, PTC124 had a very good safety proile and the functional rescue of protein translated, 
with 34% of subjects taking the drug showing qualitative increase in immunoluorescence for the protein in post 
treatment muscle biopsies. Furthermore, in phase 2 trials, patients treated with the drug were able to walk further 
in standardised timed tests than those taking placebo, and while this did not meet signiicance, other endpoints 
did, including slowing of disease progression26. his level of rescue is comparable to the results shown herein, 
suggesting that only partial recovery of the protein may facilitate a functional improvement in vivo.
he mechanism of action of TRIDs is not completely understood but the drugs are thought to interfere with 
ribosomal idelity so that a near-cognate aminoacyl tRNA can bind at the site of a premature stop codon resulting 
in the incorporation of another amino acid in its place, allowing translation to continue15. It is also postulated that 
the readthrough efect of TRIDs is dependent not just on the nonsense variant but also in the context of the local 
sequence, the particular bases that make up the stop codon and the stability of the resulting protein. he TRID 
PTC124 performs best when acting on the UAG stop codon followed by a cytosine28, which is the sequence of 
the MERTK premature stop codon presented here and may account for the eiciency observed in this case. We 
acknowledge that this is the second MERTK iPSC RPE model29, however it is the irst to show a treatment efect 
and amelioration of function.
iPSC models ofer an attractive alternative to animal models as they allow the study of human tissue. he 
Royal College of Surgeons (RCS) rat, a natural animal model that harbours a spontaneous homozygous deletion 
in the MERTK gene has been used for decades as a general model of retinal degeneration30, 31 and a speciic model 
of MERTK related retinal disease. However, the RCS genotype32, 33, does not recapitulate any observed in man10 
thus diminishing its use as a clinical model in the post genome age.
Conclusion
We have been able to create and characterise iPSC derived RPE cells with MERTK deiciency to create an accurate 
in vitro model of human disease. Our results show that the MERTK-RPE cells have a defect in the engulfment of 
POS. Using the translational readthrough inducing drugs G418 and PTC124 we were able to restore expression 
of the MERTK gene to detectable full-length protein in the MERTK deicient RPE. Moreover, the PTC124 com-
pound was able to rescue 12% of the phagocytic function of the RPE cells. It may be possible, therefore, to use 
TRIDs to treat retinitis pigmentosa due to nonsense variants in MERTK, which hitherto has no efective therapy. 
Furthermore, human iPSC derived models may also be useful to bridge the gap between preclinical animal stud-
ies and clinical trials to test other treatments such as gene therapies.
Materials and Methods
Clinical phenotyping. Fundus photos were captured with a digital camera and Topcon image capture sys-
tem. Wideield images and autoluorescence images were captured using the Optos 200Tx retinal imaging system. 
Optical coherence tomography images and autoluorescence images were captured using a Heidelberg Spectralis. 
Microperimetry was performed using the Nidek MP-1 microperimeter set to Humphrey 10-2(20 db) with a white 
200 ms Goldman III stimulus and a white 2° single cross ixation target. Adaptive optics (AO) images were cap-
tured using the Imagine Eyes rtx1™ Adaptive Optics Retinal Camera.
Generation of ibroblasts from a skin biopsy. he research adhered to the tenants of the Declaration of 
Helsinki and was approved by the Moorields Eye Hospital Ethics Committee and the Health Research Authority 
NRES Committee London. Informed, written consent was gained and a biopsy was obtained from an individual 
with a MERTK variant and ibroblasts cultivated from it as previously described16, 34.
Reprogramming of ibroblasts. Control ibroblasts (BJ line) were obtained from Stemgent. MERTK and 
control ibroblasts were reprogrammed to iPSC with episomal delivery of SOX2, OCT3/4, KLF4, L-MYC and 
LIN28 (27077, 27078, 27080, Addgene) using a protocol that has previously been described16, 35.
hese stem cells had a normal morphology, expressed markers of pluripotency, had a normal karyotype and 
were able to diferentiate into endoderm, mesoderm and ectoderm (Figure S1D–F).
Maintenance of iPSC, generation of RPE. iPSC colonies were cultured on Matrigel hESC-qualiied 
matrix (354277, BD Biosciences) in Essential 8 (A1517001, hermo Fisher). Once 80% conluent, the media was 
changed to Diferentiation Media17. From here on, cultures were fed twice weekly for at least a further 8 weeks 
until pigmented foci were observed. hese pigmented foci were isolated manually and puriied, fed twice weekly 
with X-VIVO 10 (LZBE 04-743Q, Lonza) with gentamicin (hermoFisher). All experiments were performed with 
passage 2 RPE aged 8 to 16 weeks.
phagocytosis assay. Photoreceptor outer segments (POS) were puriied from fresh sheep eyes obtained 
from a local abattoir (Chelmsford, UK) using a previously published protocol19. Some POS were labeled with 
Fluorescein-5-Isothiocyanate (FITC ‘Isomer I’, F1906, hermoFisher). Samples for electron microscopy analysis 
of phagocytosis used unlabeled POS. he labeled or unlabeled POS were added to DMEM with 4.5 g/L glucose, 
L-glutamine and pyruvate (41966029 hermoFisher), 10 mM GAS6 (885-GS-050, R&D systems, MN, USA) and 
10% FBS (10099141, hermoFisher) and exposed to the iPSC derived RPE at a ratio of 10 POS per cell for 6 hours 
or 20 hours. At the endpoint, the cells were ixed in 4% PFA at 4 C for 20 mins, permeabilised with 0.3% triton 
in block solution (1X PBS, BSA 0.5%, Glycine 1%, Sodium Azide 0.1%) and stained with rhodamine phalloidin 
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(R415, hermoFisher) and Hoechst (33342 hermoFisher) for 20 mins in block solution and analysed on a Zeiss 
LSM700 confocal microscope. Z stack confocal analysis was undertaken to measure how many POS were inter-
nalised in a 101.5 µm by 101.5 µm area, using the orthogonal view function.
translational readthrough inducing drug assay. he media was changed 3 days prior to the assay 
to media containing no gentamicin. The small molecule TRIDs G418 (A1720, Sigma) or PTC124 (S6003, 
Selleckchem, Munich, Germany) were added to the X-VIVO 10 at the desired concentration and this media 
added to the cells at 24, 6 and 2 hours prior to lysis for Western blot or ixing for immunocytochemistry. In the 
experiments assessing TRID efect on phagocytosis, the G418 or PTC124 was added to the cells in X-VIVO 10, 
at 28 and 10 hours prior ixing for analysis. At 6 hours prior to ixing, the drugs were added to the POS/DMEM/
GAS6/FBS mixture outlined in the phagocytosis assay section.
electron microscopy. Samples were prepared using standard Epon embedding methods and viewed on a 
JEOL 1010 TEM. Images were taken with a Gatan Orius SC100B charge-coupled device camera and analysed with 
Gatan Digital Micrograph17.
Immunocytochemistry. Samples were ixed in 4% paraformaldehyde and permeabilised with 0.3% tri-
ton in block solution (1X PBS, BSA 0.5% (A7906, Sigma), Glycine 1%, Sodium Azide 0.1%) and blocked over-
night in block solution. Primary (MERTK, Abcam ab52968, 1:1000; PMEL17, Dako HMB45, 1:1000; PAX6, 
Covance PRB278P, 1:200; CRALBP, hermoFisher MA1813, 1:200; RPE65, Millipore MAB5428; ITAV, Abcam 
92797, 1:500) and secondary (Alexaluor, hermoFisher, 1:200) antibodies applied for 1 hour each treated with 
Hoechst (33342, hermoFisher) for 30 seconds and mounted in ProLong® Gold Antifade Mountant (P10144, 
hermoFisher).
Immunohistochemistry. All samples were ixed in 4% paraformaldehyde for 20 mins and washed with PBS 
and prepared with a previously published protocol17. Immunohistochemistry of samples on slides carried out in 
a dark humidiied chamber. Slides were stained as for immunocytochemistry.
Western blot. Samples for Western blotting were lysed prepared using previously published protocol20 
and separated in a 4–20% Mini-PROTEAN® TGXTM Gel (4561093, Bio-Rad, UK). he separated protein in the 
gel was transferred using the Trans-Blot® TurboTM Transfer system (1704155, Bio-Rad, UK). he membrane 
was blocked overnight and then incubated with primary antibody for 1 hour (MERTK, Abcam 52968, 1:1000; 
GAPDH, Everest EB07069, 1:2000; CRALBP, hermoFisher MA1813, 1:1000), washed and incubated with horse-
radish peroxidase-conjugated secondary antibodies (P0448, P0449, Dako, UK). he membrane was incubated in 
Amersham ECL prime (GERPN2232, Sigma) and images collected on the ChemiDoc™ MP System (1708280, 
Bio-Rad, UK).
Genomic DNA extraction. Genomic DNA was extracted from the fibroblasts using the GeneElute™ 
Mammalian Genomic DNA mini prep kit (G1N10, Sigma).
Sequencing. Samples for sequencing were ampliied using Advantage® 2 PCR Kit (639206, Clonetech) in a 
ProlexTM PCR machine (4484077, hermoFisher). PCR products were separated on an agarose gel, and bands 
extracted and puriied using the QIAquick Gel Extraction Kit (28704, Qiagen). Cycle sequencing was performed 
using the BigDye Terminator v3.1 sequencing kit (4337455, hermoFisher). Extension products were puriied 
using EDTA/NaOAc/EtOH precipitation. Sample electrophoresis was performed using a 3730 DNA Analyser 
(hermoFisher). Sequences were evaluated in MacVector (NC, USA) and compared to NCBI MERTK genomic 
(NG_011607.1) and mRNA (NM_006343.2) sequences.
Rt pCR. RNA was extracted using TRIzol® Reagent (15596026, hermoFisher) Reverse transcription was 
performed with the SuperScript® III First-Strand Synthesis System for RT-PCR (18080-051 hermoFisher). 
Polymerase chain reactions (PCR) were performed using the Advantage® 2 PCR Kit (639206, Clonetech) with 
50 µl reaction volume in a ProlexTM PCR machine (4484077, hermoFisher).
statistics. All statistics are derived from the student t-test.
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